Laboratorios Farmacéuticos Rovi, S.A. announces that ROIS Phoenix Inc. (the “Buyer”), a wholly owned subsidiary of ROVI Pharma Industrial Services, S.A.U., has entered into an Asset Purchase Agreement with Bristol Myers Squibb (“BMS”) for the acquisition of a drug manufacturing facility located in Phoenix, Arizona (United Stated of America) (the “Facility”) together with a series of assets and liabilities related thereto (the “Transaction”).

As part of the Transaction, the Buyer has entered into a Toll Manufacturing Agreement with BMS, which regulates the conditions under which the Buyer will continue to manufacture products for BMS at the Facility. The agreement has an initial term of five years from the closing of the Transaction and provides for a minimum payment of 50 million dollars for each year of the contract.

The acquisition of the Facility will be made for a price which is not material for ROVI and will be subject to the fulfilment of certain customary conditions precedent set out for this type of transaction. The completion of the Transaction is expected to take place during the first half of 2026.

You can access the replay of the call by clicking here: 

ROVI Corporate Communication